Trial
NCT05718882
Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
UnknownTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
RenJi Hospital
Collaborators
—
Condition
Liver Cancer
Intervention
Lenvatinib Oral Product Plus VIC1911
Why stopped
The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg, 150 mg, 200 mg BID) was scientifically unjustified, lacking prior clinical safety data to support such starting doses when combined with lenvatinib in HC
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-30